Comments
Drug maker Lupin has launched generic version of Diovan tablets, a hypertension drug, in the U.S. market after getting approval from the American health regulator.
Lupin Pharmaceuticals Inc, the U.S.-based subsidiary of the company, has launched its Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg and 320 mg in the US market after getting nod from the US Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
The Mumbai-based firm’s product, which is indicated for the treatment of hypertension, is the generic version of Novartis Pharmaceuticals Corporation’s Diovan tablets, it added.
According to IMS MAT September, 2014 sales data, Diovan tablets had annual U.S. sales of $2.08 billion.
“This is Lupin’s fourth abbreviated new drug application (ANDA) approvals in three weeks. These approvals and the subsequent launches represent a collective market size of over $5 billion for Lupin,” the company said.
Lupin shares were trading at Rs 1,398 on the BSE, down 2.22 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.